These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 28943185)
1. A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets. Brzezniak C; Oronsky B; Aggarwal R Eur Urol; 2018 Feb; 73(2):306-307. PubMed ID: 28943185 [No Abstract] [Full Text] [Related]
2. Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma. Lee MJ; Tomita Y; Yuno A; Lee S; Abrouk NE; Oronsky B; Caroen S; Trepel JB Expert Opin Investig Drugs; 2021 Feb; 30(2):177-183. PubMed ID: 33306414 [No Abstract] [Full Text] [Related]
3. Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets. Ojemuyiwa M; Zeman K; Spira A; Oronsky B; Ray C; Trepel JB; Lee MJ; Onyiuke I; Brzezniak C Clin Case Rep; 2018 Dec; 6(12):2478-2481. PubMed ID: 30564353 [TBL] [Abstract][Full Text] [Related]
4. Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. Zafeiriou Z; Bianchini D; Chandler R; Rescigno P; Yuan W; Carreira S; Barrero M; Petremolo A; Miranda S; Riisnaes R; Rodrigues DN; Gurel B; Sumanasuriya S; Paschalis A; Sharp A; Mateo J; Tunariu N; Chinnaiyan AM; Pritchard CC; Kelly K; de Bono JS Eur Urol; 2019 Jan; 75(1):184-192. PubMed ID: 30340782 [TBL] [Abstract][Full Text] [Related]
5. Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report. Brzezniak C; Oronsky B; Scicinski J; Caroen S; Cabrales P; Dean Abrouk N; Kim MM; Brown JF; Reid TR; Larson C; Oronsky A; Day R; Degesys A; Carter CA Oncol Res Treat; 2016; 39(11):720-723. PubMed ID: 27855386 [TBL] [Abstract][Full Text] [Related]
6. Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal. Dorff TB; Wilkins C; Hepgur M; Quinn DI Clin Genitourin Cancer; 2014 Apr; 12(2):e55-8. PubMed ID: 24331572 [No Abstract] [Full Text] [Related]
8. Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases. Kim MM; Parmar H; Cao Y; Knox SJ; Oronsky B; Scicinski J; Lawrence TS; Lao CD Neuro Oncol; 2016 Mar; 18(3):455-6. PubMed ID: 26769715 [No Abstract] [Full Text] [Related]
9. Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer. Hutson PR Clin Pharmacokinet; 2015 Oct; 54(10):989-91. PubMed ID: 26077984 [No Abstract] [Full Text] [Related]
10. Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix. Tangjitgamol S; Manusirivithaya S; Choomchuay N; Leelahakorn S; Thawaramara T; Pataradool K; Suekwatana P J Obstet Gynaecol Res; 2007 Apr; 33(2):218-24. PubMed ID: 17441901 [TBL] [Abstract][Full Text] [Related]
11. Comment on: "Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer". Gibbons JA Clin Pharmacokinet; 2016 Jan; 55(1):131-2. PubMed ID: 26649871 [No Abstract] [Full Text] [Related]
12. Rockets, radiosensitizers, and RRx-001: an origin story part I. Oronsky B; Scicinski J; Ning S; Peehl D; Oronsky A; Cabrales P; Bednarski M; Knox S Discov Med; 2016 Mar; 21(115):173-80. PubMed ID: 27115167 [TBL] [Abstract][Full Text] [Related]
13. The biology of castration-resistant prostate cancer. Lian F; Sharma NV; Moran JD; Moreno CS Curr Probl Cancer; 2015; 39(1):17-28. PubMed ID: 25547388 [No Abstract] [Full Text] [Related]
14. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Das DS; Ray A; Das A; Song Y; Tian Z; Oronsky B; Richardson P; Scicinski J; Chauhan D; Anderson KC Leukemia; 2016 Nov; 30(11):2187-2197. PubMed ID: 27118403 [TBL] [Abstract][Full Text] [Related]
15. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Oronsky B; Paulmurugan R; Foygel K; Scicinski J; Knox SJ; Peehl D; Zhao H; Ning S; Cabrales P; Summers TA; Reid TR; Fitch WL; Kim MM; Trepel JB; Lee MJ; Kesari S; Abrouk ND; Day RM; Oronsky A; Ray CM; Carter CA Expert Opin Investig Drugs; 2017 Jan; 26(1):109-119. PubMed ID: 27935336 [TBL] [Abstract][Full Text] [Related]